Affordable Access

Access to the full text

MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer’s disease

Authors
  • Ringland, Charis1, 2
  • Schweig, Jonas Elias1
  • Eisenbaum, Maxwell1, 2
  • Paris, Daniel1
  • Ait-Ghezala, Ghania1, 2
  • Mullan, Michael1, 2
  • Crawford, Fiona1, 2, 3
  • Abdullah, Laila1, 2, 3
  • Bachmeier, Corbin1, 2, 4
  • 1 The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA , Sarasota (United States)
  • 2 The Open University, Milton Keynes, UK , Milton Keynes (United Kingdom)
  • 3 James A. Haley Veterans’ Hospital, Tampa, FL, USA , Tampa (United States)
  • 4 Bay Pines VA Healthcare System, Bay Pines, FL, USA , Bay Pines (United States)
Type
Published Article
Journal
BMC Neuroscience
Publisher
Springer (Biomed Central Ltd.)
Publication Date
May 25, 2021
Volume
22
Issue
1
Identifiers
DOI: 10.1186/s12868-021-00643-2
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundMatrix metallopeptidase 9 (MMP9) has been implicated in a variety of neurological disorders, including Alzheimer’s disease (AD), where MMP9 levels are elevated in the brain and cerebrovasculature. Previously our group demonstrated apolipoprotein E4 (apoE4) was less efficient in regulating MMP9 activity in the brain than other apoE isoforms, and that MMP9 inhibition facilitated beta-amyloid (Aβ) elimination across the blood–brain barrier (BBB)MethodsIn the current studies, we evaluated the impact of MMP9 modulation on Aβ disposition and neurobehavior in AD using two approaches, (1) pharmacological inhibition of MMP9 with SB-3CT in apoE4 x AD (E4FAD) mice, and (2) gene deletion of MMP9 in AD mice (MMP9KO/5xFAD)ResultsTreatment with the MMP9 inhibitor SB-3CT in E4FAD mice led to reduced anxiety compared to placebo using the elevated plus maze. Deletion of the MMP9 gene in 5xFAD mice also reduced anxiety using the open field test, in addition to improving sociability and social recognition memory, particularly in male mice, as assessed through the three-chamber task, indicating certain behavioral alterations in AD may be mediated by MMP9. However, neither pharmacological inhibition of MMP9 or gene deletion of MMP9 affected spatial learning or memory in the AD animals, as determined through the radial arm water maze. Moreover, the effect of MMP9 modulation on AD neurobehavior was not due to changes in Aβ disposition, as both brain and plasma Aβ levels were unchanged in the SB-3CT-treated E4FAD animals and MMP9KO/AD mice compared to their respective controls.ConclusionsIn total, while MMP9 inhibition did improve specific neurobehavioral deficits associated with AD, such as anxiety and social recognition memory, modulation of MMP9 did not alter spatial learning and memory or Aβ tissue levels in AD animals. While targeting MMP9 may represent a therapeutic strategy to mitigate aspects of neurobehavioral decline in AD, further work is necessary to understand the nature of the relationship between MMP9 activity and neurological dysfunction.

Report this publication

Statistics

Seen <100 times